Helius Medical Technologies Files 8-K
Ticker: HSDT · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1610853
| Field | Detail |
|---|---|
| Company | Helius Medical Technologies, Inc. (HSDT) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, sec-filing
TL;DR
Helius Medical Technologies filed an 8-K on Jan 13, 2025. Check it out.
AI Summary
On January 13, 2025, HELIUS MEDICAL TECHNOLOGIES, INC. announced an "Other Event" filing with the SEC. The filing details are contained within a Form 8-K, with the accession number 0001104659-25-003623. The company is incorporated in Delaware and its principal executive offices are located at 642 Newtown Yardley Road, Suite 100, Newtown, PA 18940.
Why It Matters
This filing indicates a material event has occurred for Helius Medical Technologies, Inc., requiring public disclosure. Investors should review the filing for details on the nature of this event.
Risk Assessment
Risk Level: low — The filing is a standard 8-K current report, and the provided text does not contain specific financial or operational details that would indicate high risk.
Key Players & Entities
- HELIUS MEDICAL TECHNOLOGIES, INC. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- 0001104659-25-003623 (filing_id) — Accession Number
- Delaware (jurisdiction) — State of incorporation
- 642 Newtown Yardley Road, Suite 100, Newtown, PA 18940 (address) — Address of principal executive offices
FAQ
What is the specific nature of the "Other Event" reported in the 8-K filing?
The provided text does not specify the nature of the "Other Event"; it only indicates that an 8-K filing was made on January 13, 2025, under this item.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 13, 2025.
What is the company's full legal name and state of incorporation?
The company's full legal name is HELIUS MEDICAL TECHNOLOGIES, INC., and it is incorporated in Delaware.
Where are HELIUS MEDICAL TECHNOLOGIES, INC.'s principal executive offices located?
The principal executive offices of HELIUS MEDICAL TECHNOLOGIES, INC. are located at 642 Newtown Yardley Road, Suite 100, Newtown, PA 18940.
What is the accession number for this 8-K filing?
The accession number for this 8-K filing is 0001104659-25-003623.
Filing Stats: 398 words · 2 min read · ~1 pages · Grade level 12.6 · Accepted 2025-01-15 08:40:41
Key Financial Figures
- $0.001 — whichregistered Class A Common Stock, $0.001 par value HSDT The Nasdaq Stock Mar
Filing Documents
- tm253406d1_8k.htm (8-K) — 24KB
- tm253406d1_8kimg001.jpg (GRAPHIC) — 3KB
- 0001104659-25-003623.txt ( ) — 201KB
- hsdt-20250113.xsd (EX-101.SCH) — 3KB
- hsdt-20250113_lab.xml (EX-101.LAB) — 33KB
- hsdt-20250113_pre.xml (EX-101.PRE) — 22KB
- tm253406d1_8k_htm.xml (XML) — 4KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38445 36-4787690 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 642 Newtown Yardley Road , Suite 100 Newtown , PA 18940 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code : ( 215 ) 944-6100 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on whichregistered Class A Common Stock, $0.001 par value HSDT The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On January 13, 2025, the Centers for Medicare and Medicaid Services posted final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies fee schedule payment rates for the PoNS Controller (HCPCS Code A4593), consistent with its preliminary reimbursement determination. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HELIUS MEDICAL TECHNOLOGIES, INC. Dated: January 15, 2025 By: /s/ Jeffrey S. Mathiesen Jeffrey S. Mathiesen Chief Financial Officer, TreasurerandSecretary